Literature DB >> 12820749

Three fatal cases of PMA and PMMA poisoning in Denmark.

Sys Stybe Johansen1, A Carsten Hansen, Irene Breum Müller, Jytte Banner Lundemose, Maria-B Franzmann.   

Abstract

Paramethoxyamphetamine (PMA) and paramethoxymetamphetamine (PMMA) are methoxylated phenylethylamine derivatives with effects similar to methylenedioxymetamphetamine (MDMA) and sold as such. However, PMA and PMMA are more potent than MDMA, but have a slower onset of action, which encourages users to take more. Three fatal cases involving PMA and PMMA in Denmark in year 2000 are investigated including history, pathological, and toxicological findings. The methods used for extraction, identification, and quantitation of PMA and PMMA are described. In two of the cases, lethal postmortem blood concentrations of PMA and PMMA were determined at 3.4 and 3.3 mg/kg (case 1) and 0.78 and 0.68 mg/kg (case 3), respectively. In addition, other drugs such as MDMA, tetrahydrocannabinol, cocaine, and alcohol were involved in these cases. In the third case, death occurred four days after the ingestion of tablets containing PMA and PMMA, and therefore only low postmortem concentrations of PMA and amphetamine were detected. However, in a serum sample taken at admission to the hospital, PMA and PMMA were found, but not quantitated. It is believed that the cause of death in case 2, multiple-organ failure, was caused by overdoses of PMA and PMMA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820749     DOI: 10.1093/jat/27.4.253

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  8 in total

1.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

2.  Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats.

Authors:  Cesar A Romero; Diego A Bustamante; Gerald Zapata-Torres; Michel Goiny; Bruce Cassels; Mario Herrera-Marschitz
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.911

3.  Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.

Authors:  Tibor M Brunt; Maarten W Koeter; Raymond J M Niesink; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

4.  PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice.

Authors:  Eun-Joo Shin; Duy-Khanh Dang; Hai-Quyen Tran; Yunsung Nam; Ji Hoon Jeong; Young Hun Lee; Kyung Tae Park; Yong Sup Lee; Choon-Gon Jang; Jau-Shyong Hong; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2016-09-10       Impact factor: 3.921

5.  Effects of MDMA on body temperature in humans.

Authors:  Matthias E Liechti
Journal:  Temperature (Austin)       Date:  2014-10-31

6.  Investigation of Biotransformation Products of p-Methoxymethylamphetamine and Dihydromephedrone in Wastewater by High-Resolution Mass Spectrometry.

Authors:  Juliet Kinyua; Aikaterini K Psoma; Nikolaos I Rousis; Maria-Christina Nika; Adrian Covaci; Alexander L N van Nuijs; Νikolaos S Τhomaidis
Journal:  Metabolites       Date:  2021-01-25

7.  Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters.

Authors:  Krystyna Gołembiowska; Alexandra Jurczak; Katarzyna Kamińska; Karolina Noworyta-Sokołowska; Anna Górska
Journal:  Neurotox Res       Date:  2015-10-26       Impact factor: 3.911

8.  The Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.

Authors:  Luisa Ponzoni; Daniela Braida; Gianpietro Bondiolotti; Mariaelvina Sala
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.